In short
Clinical trials are studying 89ZR-CED88004S in people with large B-cell lymphoma. These trials aim to see how well PET imaging can show CD8+ T-cells before and after CAR T-cell therapy, and to measure how the tracer is distributed in the body and tumors.
Key points
- Clinical trials are studying 89ZR-CED88004S in people with large B-cell lymphoma. The trial uses PET imaging to look at CD8+ T-cells before and after CAR T-cell therapy. It is a Phase 4, interventional study with 27 planned participants. The main goal is to measure how the tracer spreads through normal tissues and tumor lesions. The study also looks at tracer uptake and how it relates to CD8+ CAR T-cell invasion in tumors.
Trial overview
The trial titled CD8 PET imaging study before and after CAR T-cell therapy is studying 89ZR-CED88004S in people with large B-cell lymphoma. It is an interventional study, which means the research team gives the tracer and then measures the results on imaging scans.
The study is authorised and plans to enroll 27 people. The source data describes 89ZR-CED88004S as part of a PET imaging approach used before and after CAR T-cell therapy.
Who can participate
The target population in this trial is people with large B-cell lymphoma, a cancer of B cells, which are a type of white blood cell. The source data does not list more detailed entry rules, such as age limits or prior treatments.
The study focuses on patients before and after CAR T-cell therapy, so the imaging is meant to follow changes over time in the same disease setting.
What is being measured
The main outcome is the whole-body biodistribution of the tracer, which means how the tracer spreads through normal tissues and tumor lesions across the body. The study also measures heterogeneity, meaning whether the tracer signal is the same or different in different areas.
Another key measure is standardized uptake value (SUV) on the PET scan 2 days after injection. SUV is a number used to show how much tracer is taken up by a tissue or lesion.
The brief summary says the study will correlate, or compare, the pretreatment CD8+ T-cell pattern with CD8+ CAR T-cell tumor invasion, as shown by the intensity of PET-positive lesions.
Study design and phase
This is a Phase 4 trial. Phase 4 studies are generally used to learn more about a test or treatment in a broader clinical setting after it is already being used.
The intervention listed is 89ZR-CED88004S given as a 10 mg intravenous bolus injection or IV infusion. The source data does not provide further details about the full scan schedule beyond the PET scan 2 days after injection.
Why this study matters
This trial is trying to see whether PET imaging with 89ZR-CED88004S can show where CD8+ T-cells are located before treatment and how they change after CAR T-cell therapy. That may help researchers understand how immune cells move into tumors during treatment.
For patients, the important point is that this study is not mainly about treating the cancer directly. It is about using imaging to learn more about the immune response in large B-cell lymphoma.